Cargando…

Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway

Astragaloside IV (AS-IV) in improving liver cirrhosis injury in rats and its effect on the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) signaling pathway were observed. Rat model of liver cirrhosis was induced by injection of carbon tetrachloride (CC...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Rendong, Liu, Haidong, Chen, Ru, Sheng, Yunjian, Liu, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307369/
https://www.ncbi.nlm.nih.gov/pubmed/30651810
http://dx.doi.org/10.3892/etm.2018.6966
_version_ 1783382991029927936
author Wei, Rendong
Liu, Haidong
Chen, Ru
Sheng, Yunjian
Liu, Tao
author_facet Wei, Rendong
Liu, Haidong
Chen, Ru
Sheng, Yunjian
Liu, Tao
author_sort Wei, Rendong
collection PubMed
description Astragaloside IV (AS-IV) in improving liver cirrhosis injury in rats and its effect on the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) signaling pathway were observed. Rat model of liver cirrhosis was induced by injection of carbon tetrachloride (CCl(4)). A total of 36 Sprague-Dawley (SD) rats were randomly divided into three groups: the normal control group (n=10), the model control group (n=13), and the AS-IV group (n=13). The normal control group was injected with olive oil and given carboxymethyl cellulose (CMC)-Na (10 ml/kg/day), the model control group was given CMC-Na (10 ml/kg/day), and the AS-IV group underwent intragastric administration of AS-IV (20 ml/kg/day). The content of alanine transaminase (ALT) and aspartate transaminase (AST) of rats was detected. The levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-6 and IL-1β in serum were detected via enzyme-linked immunosorbent assay (ELISA). Hematoxylin and eosin (H&E) staining was applied to observe morphological changes in liver tissues. The expression of collagens in liver tissues was detected via Masson's trichrome staining. Additionally, the expression of proteins in liver tissues was detected via western blotting. Compared with those in the blank group, the levels of AST, ALT, TNF-α, IL-6 and IL-1β were higher, the expression level of collagens in liver tissues was increased, and the expression ratios of phosphorylated (p)-PI3K/PI3K, p-Akt/Akt and p-mTOR/mTOR proteins were increased in the model group. Compared with the model group, AS-IV could significantly decrease the content of AST, ALT, TNF-α, IL-6 and IL-β in serum of rats, obviously inhibit the expression of collagens in liver tissues and decrease the expression ratios of p-PI3K/PI3K, p-Akt/Akt and p-mTOR/mTOR proteins in liver tissues. AS-IV can inhibit the inflammatory response so as to reduce the expression of collagens, and its mechanism may play a key role by inhibiting the PI3K/Akt/mTOR signaling pathway.
format Online
Article
Text
id pubmed-6307369
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-63073692019-01-16 Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway Wei, Rendong Liu, Haidong Chen, Ru Sheng, Yunjian Liu, Tao Exp Ther Med Articles Astragaloside IV (AS-IV) in improving liver cirrhosis injury in rats and its effect on the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) signaling pathway were observed. Rat model of liver cirrhosis was induced by injection of carbon tetrachloride (CCl(4)). A total of 36 Sprague-Dawley (SD) rats were randomly divided into three groups: the normal control group (n=10), the model control group (n=13), and the AS-IV group (n=13). The normal control group was injected with olive oil and given carboxymethyl cellulose (CMC)-Na (10 ml/kg/day), the model control group was given CMC-Na (10 ml/kg/day), and the AS-IV group underwent intragastric administration of AS-IV (20 ml/kg/day). The content of alanine transaminase (ALT) and aspartate transaminase (AST) of rats was detected. The levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-6 and IL-1β in serum were detected via enzyme-linked immunosorbent assay (ELISA). Hematoxylin and eosin (H&E) staining was applied to observe morphological changes in liver tissues. The expression of collagens in liver tissues was detected via Masson's trichrome staining. Additionally, the expression of proteins in liver tissues was detected via western blotting. Compared with those in the blank group, the levels of AST, ALT, TNF-α, IL-6 and IL-1β were higher, the expression level of collagens in liver tissues was increased, and the expression ratios of phosphorylated (p)-PI3K/PI3K, p-Akt/Akt and p-mTOR/mTOR proteins were increased in the model group. Compared with the model group, AS-IV could significantly decrease the content of AST, ALT, TNF-α, IL-6 and IL-β in serum of rats, obviously inhibit the expression of collagens in liver tissues and decrease the expression ratios of p-PI3K/PI3K, p-Akt/Akt and p-mTOR/mTOR proteins in liver tissues. AS-IV can inhibit the inflammatory response so as to reduce the expression of collagens, and its mechanism may play a key role by inhibiting the PI3K/Akt/mTOR signaling pathway. D.A. Spandidos 2019-01 2018-11-13 /pmc/articles/PMC6307369/ /pubmed/30651810 http://dx.doi.org/10.3892/etm.2018.6966 Text en Copyright: © Wei et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Wei, Rendong
Liu, Haidong
Chen, Ru
Sheng, Yunjian
Liu, Tao
Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway
title Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway
title_full Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway
title_fullStr Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway
title_full_unstemmed Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway
title_short Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway
title_sort astragaloside iv combating liver cirrhosis through the pi3k/akt/mtor signaling pathway
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307369/
https://www.ncbi.nlm.nih.gov/pubmed/30651810
http://dx.doi.org/10.3892/etm.2018.6966
work_keys_str_mv AT weirendong astragalosideivcombatinglivercirrhosisthroughthepi3kaktmtorsignalingpathway
AT liuhaidong astragalosideivcombatinglivercirrhosisthroughthepi3kaktmtorsignalingpathway
AT chenru astragalosideivcombatinglivercirrhosisthroughthepi3kaktmtorsignalingpathway
AT shengyunjian astragalosideivcombatinglivercirrhosisthroughthepi3kaktmtorsignalingpathway
AT liutao astragalosideivcombatinglivercirrhosisthroughthepi3kaktmtorsignalingpathway